DexCom Reports Strong Q2 Earnings with Revenue Growth and Margin Expansion
DexCom (DXCM) reported second-quarter revenue of $1.31 billion, reflecting 13% growth year-over-year on a reported basis and 12% organically. U.S. revenue rose by 11%, driven by new patient starts and market share gains, while international revenue surged 19%. Non-GAAP gross profit margin improved significantly to 64.1%, up from 60.1% in the prior year period due to manufacturing efficiencies. The company raised its full-year revenue guidance to $5.18 billion–$5.25 billion, with non-GAAP operating margin expectations increased to 23.5%–24%. DexCom also reported free cash flow of $600 million for the first half of 2026 and repurchased $600 million in shares under its buyback program. DexCom highlighted progress on product development, including a planned G8 system launch by late 2027 or early 2028. The company also acquired Nutrisense to integrate nutrition insights into its offerings.
Tickers: $DXCM
Topics: free_cash_flow non-gaap_profitability revenue_growth share_repurchases